FDC Limited (NSE:FDC)
411.00
-2.25 (-0.54%)
Jul 22, 2026, 3:29 PM IST
FDC Limited Revenue
In the fiscal year ending March 31, 2026, FDC Limited had annual revenue of 21.71B INR with 2.98% growth. FDC Limited had revenue of 5.85B in the quarter ending March 31, 2026, with 18.89% growth.
Revenue
21.71B
Revenue Growth
+2.98%
P/S Ratio
3.10
Revenue / Employee
3.17M
Employees
6,857
Market Cap
67.35B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 21.71B | 628.13M | 2.98% |
| Mar 31, 2025 | 21.08B | 1.65B | 8.50% |
| Mar 31, 2024 | 19.43B | 1.59B | 8.92% |
| Mar 31, 2023 | 17.84B | 2.56B | 16.74% |
| Mar 31, 2022 | 15.28B | 1.95B | 14.61% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alembic Pharmaceuticals | 73.45B |
| Strides Pharma Science | 48.59B |
| Akums Drugs and Pharmaceuticals | 43.61B |
| Alivus Life Sciences | 25.52B |
| Aarti Pharmalabs | 18.19B |
| Innova Captab | 16.30B |
| Solara Active Pharma Sciences | 13.69B |
| Orchid Pharma | 8.11B |
FDC Limited News
- 7 weeks ago - FDC reports Rs 585 crore revenue in Q4 FY26 with 18.9% growth - Business Upturn
- 2 months ago - FDC reports 18.9% revenue growth in Q4 FY26, driven by strong export performance - Business Upturn
- 2 months ago - FDC Limited receives US FDA ANDA approval for Cefixime Oral Suspension — opens new revenue line in US antibiotic market - Business Upturn
- 4 months ago - FDC reconstitutes board committees and appoints Mohan Chandavarkar as chairman - Business Upturn
- 10 months ago - FDC receives ANDA approval from U.S. FDA for Pilocarpine Hydrochloride Ophthalmic Solution USP - Business Upturn
- 1 year ago - FDC shares drop over 3% as Q4 EBITDA falls 4.2% YoY to Rs 54 crore, net profit down 16.4% YoY - Business Upturn
- 1 year ago - FDC receives US FDA approval for Cefixime 400 mg tablets - Business Upturn
- 2 years ago - FDC shares surge 11%, leading gains in BSE Healthcare index - Business Upturn